Shim Hyun-Jeong, Shin Min-Ho, Kim Hee-Nam, Kim Jo-Heon, Hwang Jun-Eul, Bae Woo-Kyun, Chung Ik-Joo, Cho Sang-Hee
Department of Hemato-Oncology, Chonnam National University Medical School, Hwasun, Korea.
Department of Preventive Medicine, Chonnam National University Medical School, Hwasun, Korea ; Department of Jeonnam Regional Cancer Center, Chonnam National University Medical School, Hwasun, Korea.
Cancer Res Treat. 2016 Jan;48(1):71-9. doi: 10.4143/crt.2015.018. Epub 2015 May 14.
The purpose of this study is to investigate the role of fibroblast growth factor receptor 4 (FGFR4) polymorphism in esophageal cancer after chemoradiotherapy (CRT).
Peripheral blood samples from 244 patients treated with CRT for esophageal squamous cell carcinoma were assessed for the role of FGFR4 genotype on treatment response and survival.
A total of 94 patients were homozygous for the Gly388 allele, and 110 were heterozygous and 40 homozygous for the Arg388 allele. No significant association was found between the FGFR4 genotype and clinicopathological parameters. However, patients carrying the Gly388 allele showed a better overall response rate than Arg388 carriers (p=0.038). In addition, Gly388 allele patients at an earlier stage showed better overall survival (OS) and progression-free survival than Arg388 carriers. Among these, the Gly388 allele showed significantly improved OS compared to Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype.
This result suggests that the role of FGFR4 Gly388 in treatment outcomes differs according to esophageal cancer stage. It showed a predictive role in the response of esophageal cancer patients to CRT with a better trend for OS in Gly388 than Arg388 carriers in the early stages. In particular, LN-positive early-stage patients carrying the Gly388 allele showed improved OS compared to those carrying Arg388.
本研究旨在探讨成纤维细胞生长因子受体4（FGFR4）基因多态性在食管癌放化疗（CRT）后的作用。
对244例接受CRT治疗的食管鳞状细胞癌患者的外周血样本进行评估，以确定FGFR4基因型对治疗反应和生存的作用。
共有94例患者为Gly388等位基因纯合子，110例为杂合子，40例为Arg388等位基因纯合子。未发现FGFR4基因型与临床病理参数之间存在显著关联。然而，携带Gly388等位基因的患者总体反应率高于携带Arg388等位基因的患者（p=0.038）。此外，早期携带Gly388等位基因的患者总生存期（OS）和无进展生存期均优于携带Arg388等位基因的患者。其中，与无淋巴结转移组（p=0.125）相比，淋巴结转移组中携带Gly388等位基因的患者与携带Arg388等位基因的患者相比，OS显著改善（p=0.042）。然而，无论基因型如何，晚期疾病的生存结果相似。
该结果表明，FGFR4 Gly388在治疗结果中的作用因食管癌分期而异。它在食管癌患者对CRT的反应中具有预测作用，早期携带Gly388的患者OS趋势优于携带Arg388的患者。特别是，携带Gly388等位基因的淋巴结阳性早期患者与携带Arg388等位基因的患者相比，OS有所改善。
